Government pricing has spent three decades being treated as arithmetic performed after the quarter closed. On January 1, 2027, it starts behaving like a payment system, and what triggers the payment is a patient who actually received the drug.
Two federal programs are moving the government discount from the front of the transaction to the back of it. Medicare’s Maximum Fair Price is already delivered to pharmacies as a retrospective refund rather than a lower acquisition cost. Beginning January 1, 2027, a limited 340B rebate pilot does the same for covered entities, which will buy at wholesale acquisition cost and claim the difference back. In both cases the discount stops being a price and becomes a claim. A claim requires a dispense. A dispense requires a patient who made it all the way through.
What actually changed
The Medicare Drug Price Negotiation Program is no longer theoretical. Negotiated prices for the first ten Part D drugs took effect January 1, 2026, at roughly a 22 percent average reduction off net prices. Fifteen more Part D drugs follow on January 1, 2027, a group that includes the GLP-1 products, at a projected 44 percent average reduction. The 2028 cycle brings fifteen more and pulls physician-administered Part B drugs into negotiation for the first time. The statutory ceiling itself is a function of how old the product is, set at 75, 65 or 40 percent of non-federal average manufacturer price depending on years since approval.
Alongside that, HRSA announced a revised 340B Rebate Model Pilot Program on July 31, 2026. Applications closed August 24. Approval decisions are due by September 24. The pilot takes effect January 1, 2027, and it is narrow on purpose: it covers only drugs selected for Medicare negotiation in the 2026 and 2027 price applicability years, which HRSA puts at under 5.5 percent of total 340B sales. The other 94.5 percent keeps running on upfront discounts.
The narrowness is not the point. The mechanism is. An earlier version of this pilot was enjoined by the U.S. District Court for the District of Maine on December 29, 2025, on Administrative Procedure Act grounds, largely because covered entities had not been given adequate notice or consideration of the burden. The revision answered that with structure: 90 days advance notice instead of 60, rebates paid at unit level rather than package level, a 15-day inventory transition, mandatory dispute pathways, HIPAA deidentification standards, manufacturer-funded platforms, and removal from the pilot for a manufacturer that runs 5 percent or more of its payments late.
The operating dates that matter.
September 24, 2026. HRSA approval decisions on pilot applications.
January 1, 2027. The pilot takes effect, and fifteen additional Maximum Fair Prices begin.
Ten calendar days. The window a manufacturer has to pay a complete 340B rebate claim, with the clock restarting on an incomplete submission.
Fourteen days. The window a manufacturer has to authorize a Medicare Maximum Fair Price refund after receiving the data, which puts most refunds in a pharmacy’s account near 21 days from the date of service.
The discount used to arrive before the patient. Now it arrives after.
Under the model everyone built their systems around, a covered entity bought at the ceiling price. The discount was embedded in acquisition. There was no gap to finance and no claim to substantiate, because the price itself was the proof.
Under a rebate model, the entity buys at wholesale acquisition cost, dispenses, submits a claim and waits. That gap is short on paper and expensive in practice, because it repeats on every unit, every day, indefinitely. HRSA’s own estimate puts the average administrative cost near $34,320 per covered entity per year, and that figure does not include the working capital.
That matters commercially, not just operationally. A rural hospital or a grant-funded clinic that cannot comfortably float wholesale acquisition cost has one obvious lever, and it is the formulary. Stocking decisions are where a financing problem turns into an access problem.
Three federal prices, one dispense record
The harder problem is not cash. It is proof. Before a manufacturer pays a Maximum Fair Price refund, it has to know whether that unit was already discounted under 340B. Before it pays a 340B rebate, it has to know whether the same unit will be billed to Medicaid. Non-duplication has always been the quiet failure point in government pricing, and it was survivable when the discounts were embedded in a price and reconciled quarterly.
Once the discount is a payment, non-duplication has to resolve at the unit, in days, against a claim. There is only one artifact that can carry that determination, and it is the dispense record. Government pricing has therefore just inherited a dependency on patient-level transaction data that it never had before.
Medicaid already taught this lesson
None of this is unprecedented. The Medicaid rebate cap came off on January 1, 2024, and with it went the floor. A unit rebate amount can now exceed 100 percent of average manufacturer price, which means a manufacturer can pay more in rebate than it collected on the sale. The formula no longer has a backstop, so every input feeding it carries real money.
The lesson that generalized out of that change is simple. When a statutory formula loses its ceiling or its floor, data accuracy stops being a compliance chore and becomes a balance sheet item. The rebate model does the same thing to timing that the cap removal did to magnitude.
Where this lands in the patient journey
This is where government pricing stops being a finance topic. The 10 Exits of Therapy™ describe the ten places a patient can leave between diagnosis and a first dose. Four of them sit directly on top of what a rebate model now measures: Coverage, Authorization, Affordability and Fulfillment.
A patient who leaves at Authorization does not generate a dispense. No dispense, no claim. No claim, no rebate, no refund, and nothing to reconcile. The leakage was always real. What is new is that the same friction now removes the evidence that would have supported the discount, so it shows up twice in the same quarter.
Under a rebate model that sentence describes your government discounts too. A rebate you believe you are owed on a dispense that never happened is not a receivable. It is a forecast.
What to do before January 1
- Confirm scope. The pilot reaches only products selected for Medicare negotiation in the 2026 and 2027 price applicability years. Everything else stays on upfront discounts, so the first question is whether you are in it at all.
- Name an owner for the ten-day clock. A payment obligation measured in calendar days does not belong to a quarterly close calendar, and it does not survive being handled as an exception.
- Rebuild the Gross-to-Net accrual as a claim-triggered payable. A reserve estimated from history and a payable triggered by a submitted claim behave differently in every month that volume moves.
- Get non-duplication logic to unit level now. Resolving it after the first dispute means resolving it in front of a covered entity that has already been paid late.
- Treat covered entity liquidity as commercial risk. Model what happens to volume if entities that cannot finance wholesale acquisition cost change what they stock.
- Instrument the exits. If you cannot see where patients leave, you cannot forecast what you will owe, what you will reclaim, or which of the two will surprise you first.
The part that does not change
The statute sets the price. Operations decide whether you ever realize it. Gross-to-Net has always been the financial echo of how well the enterprise executed the patient journey, and the enterprise’s job in that journey is narrow and unglamorous. It develops, manufactures, prices, contracts, distributes and supports. It does not diagnose, prescribe, dispense or treat. Everything it can control sits on the supply side of a decision a clinician and a patient make together.
What a rebate model changes is the delay. Friction used to show up as a volume miss two quarters later. Now it shows up as a claim that was never filed, on a payment cycle measured in days. The distance between patient friction and revenue leakage just got a lot shorter.
The ten places a patient can leave are on the philosophy page. The 340B companion piece is The Many Faces of 340B, and the rebate-side version of the same measurement problem is in You Can Be Exactly Right About the Wrong Number. Definitions for the terms used here are in the glossary, and the rest of the writing is on the blog. The patient-side view of the same ten exits is at Where did your treatment stop? Reading government-program utilization and coverage posture by state and by site is what NaviCuris is built to do.
Primary sources.
- Notice Regarding 340B Rebate Model Pilot Program, Federal Register, August 3, 2026.
- HRSA Announces Revised 340B Rebate Model Pilot Program, July 31, 2026.
- Medicare Transaction Facilitator Overview for Dispensing Entities, CMS.
- Key Facts About Medicare Drug Price Negotiation, KFF.
- Medicaid Drug Rebate Program final rule, CMS.
Program terms described here reflect publicly available federal guidance and notices as of September 11, 2026, and are subject to change, agency discretion and litigation. This article is commentary, not legal, tax, regulatory or pricing advice. Figures cited are the agencies’ own published estimates. The views expressed are my own and are not made on behalf of any current or former employer. All trademarks belong to their respective owners.
Free by email
The 5 Layers of GTN™, in your inbox
Gross-to-Net from someone who has run it. Tuesdays and Thursdays.
Subscribe on Substack